Advanced

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.

Poplin, Elizabeth; Wasan, Harpreet; Rolfe, Lindsey; Raponi, Mitch; Ikdahl, Tone; Bondarenko, Ihor; Davidenko, Irina; Bondar, Volodymyr; Garin, August and Boeck, Stefan, et al. (2013) In Journal of Clinical Oncology 31(35). p.4453-4461
Abstract
Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression.
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Clinical Oncology
volume
31
issue
35
pages
4453 - 4461
publisher
American Society of Clinical Oncology
external identifiers
  • wos:000328817400012
  • pmid:24220555
  • scopus:84894297251
ISSN
1527-7755
DOI
10.1200/JCO.2013.51.0826
language
English
LU publication?
yes
id
9d49128d-481e-4770-b190-4102eca35e30 (old id 4179523)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24220555?dopt=Abstract
date added to LUP
2013-12-03 20:55:50
date last changed
2019-02-03 03:06:32
@article{9d49128d-481e-4770-b190-4102eca35e30,
  abstract     = {Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression.},
  author       = {Poplin, Elizabeth and Wasan, Harpreet and Rolfe, Lindsey and Raponi, Mitch and Ikdahl, Tone and Bondarenko, Ihor and Davidenko, Irina and Bondar, Volodymyr and Garin, August and Boeck, Stefan and Ormanns, Steffen and Heinemann, Volker and Bassi, Claudio and Evans, T R Jeffrey and Andersson, Roland and Hahn, Hejin and Picozzi, Vince and Dicker, Adam and Mann, Elaina and Voong, Cynthia and Kaur, Paramjit and Isaacson, Jeff and Allen, Andrew},
  issn         = {1527-7755},
  language     = {eng},
  number       = {35},
  pages        = {4453--4461},
  publisher    = {American Society of Clinical Oncology},
  series       = {Journal of Clinical Oncology},
  title        = {Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.},
  url          = {http://dx.doi.org/10.1200/JCO.2013.51.0826},
  volume       = {31},
  year         = {2013},
}